ClinicalTrials.gg
CompletedNCT04739059Updated Jun 2, 2026Results posted

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

A Phase 3 interventional study of CSL312 in Hereditary Angioedema, sponsored by CSL Behring. Completed at 44 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.

Started
2021
with 1 other
Phase 3
5 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 7th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Angioedemas, Hereditary by CSL Limited, or all of them as a file.
02

Study summary

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged ≥ 12 years
  • Diagnosed with clinically confirmed C1-INH HAE
  • Experienced ≥ 3 HAE attacks during the 3 months before Screening
  • Participated in the Run-in Period for at least 1 month (CSL312-naïve subjects only)
  • Experienced at least an average of 1 HAE attack per month during the Run-in Period

Exclusion criteria

Exclusion Criteria:

  • Concomitant diagnosis of another form of angioedema, such as idiopathic or acquired angioedema or recurrent angioedema associated with urticaria
  • Use of C1-INH products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis against HAE attacks at least 2 weeks before the first day of the Run-in Period
  • Use of monoclonal antibodies such as lanadelumab (Takhzyro®) 3 months before the first day of the Run-in Period.
  • Female subjects use estrogen-containing oral or hormone replacement therapy within 4 weeks prior to screening
  • Female or male subjects who are fertile and sexually active not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 30 days after receipt of the last dose of CSL312
  • Pregnant, breastfeeding, or not willing to cease breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    CSL312

    Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously

    Biological: CSL312

Interventions

  • BiologicalCSL312

    Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody

    Also known as: Factor XIIa inhibitor monoclonal antibody, garadacimab

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    Time frame: Approximately up to 54 months

  2. Percentage of Participants With TEAE

    The percentage of participants was rounded to one place of decimal.

    Time frame: Approximately up to 54 months

  3. Number of TEAE

    Time frame: Approximately up to 54 months

  4. TEAE Rates Per Injection

    The TEAE rate per injection was calculated as the number of TEAE/ total number of injections. The number of injections was defined as the total injections received by participants during the respective safety evaluation period.

    Time frame: Approximately up to 54 months

  5. TEAE Rates Per Participant Year

    The TEAE rate per participant year was calculated as the total number of TEAE/ participant years. Participant years was defined as the sum of the time (in years) that participant were exposed to study treatment during the respective safety evaluation period.

    Time frame: Approximately up to 54 months

Secondary outcomes

  1. The Time-normalized Number (Per Month) of Hereditary Angioedema (HAE) Attacks During the Run-in Period and Treatment Period

    Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*30.4375.

    Time frame: Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months

  2. The Time-normalized Number (Per Year) of HAE Attacks During Treatment Period

    Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*365.25.

    Time frame: Approximately up to 52 months

  3. Percentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period

    The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as: 100\*(1- time normalized number of HAE attacks per month during Treatment Period/time-normalized number of HAE attacks per month during Run-in Period).

    Time frame: Run-in Period: Up to 60 days and Treatment Period: Approximately up to 52 months

  4. Number of Participants With Percentage Reduction (of >=50%, >=70%, >=90%, and 100%) in HAE Attacks

    The number of participants who achieved a percentage reduction in HAE attacks of \>=50% (also considered as responders), \>=70%, \>=90%, and 100% (attack free) during the Treatment Period compared with the Run-in Period. The percentage reduction in the time-normalized number of HAE attacks per month was calculated as 100\*\[1 - (time-normalized number of HAE attacks per month under CSL312 treatment / time-normalized number of HAE attacks per month during Run-in Period)\].

    Time frame: Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months

  5. The Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment

    Time-normalized number of HAE attacks per month requiring on demand treatment was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*30.4375.

    Time frame: Approximately up to 52 months

  6. The Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment

    Time-normalized number of HAE attacks requiring on demand treatment per year was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*365.25.

    Time frame: Approximately up to 52 months

  7. The Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks

    Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\]\*30.4375.

    Time frame: Approximately up to 52 months

  8. The Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks

    Time-normalized number of moderate or severe HAE attacks per year during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks /length of participant treatment in days\]\*365.25.

    Time frame: Approximately up to 52 months

  9. Number of Participants Rating Their Response to Therapy as Good or Excellent

    Number of participants rating their response to therapy as good or excellent was evaluated as per Subject's Global Assessment of Response to Therapy (SGART) questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure.

    Time frame: At Months 12, 24, and 36

  10. Percentage of Participants Rating Their Response to Therapy as Good or Excellent

    Percentage of participants rating their response to therapy as good or excellent was evaluated as per SGART questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure. The percentage of participants was rounded to one place of decimal.

    Time frame: At Months 12, 24, and 36

  11. Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

    Time frame: Approximately up to 54 months

  12. Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

    The percentage of participants was rounded to one decimal place.

    Time frame: Approximately up to 54 months

  13. Number of Participants Experiencing TEAE by Severity

    Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: Approximately up to 54 months

  14. Percentage of Participants Experiencing TEAE by Severity

    Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one decimal place.

    Time frame: Approximately up to 54 months

  15. Number of Participants Experiencing Adverse Events of Special Interest (AESI)

    The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.

    Time frame: Approximately up to 54 months

  16. Percentage of Participants Experiencing AESI

    The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.

    Time frame: Approximately up to 54 months

  17. Number of Participants With Laboratory Findings Reported as TEAE

    Time frame: Approximately up to 54 months

  18. Percentage of Participants With Laboratory Findings Reported as TEAE

    The percentage of participant was rounded to one place of decimal.

    Time frame: Approximately up to 54 months

  19. Number of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE

    Time frame: Approximately up to 54 months

  20. Percentage of Participants With nC1-INH Experiencing TEAE

    Time frame: Approximately up to 54 months

  21. Number of Participants With Anti-CSL312 Antibodies

    Time frame: At Day 1, Months 6, 12, 36 and 43 (end of treatment [EOT])

  22. Percentage of Participants With Anti-CSL312 Antibodies

    The percentage of participants was rounded to one decimal place.

    Time frame: At Day 1, Months 6, 12, 36 and 43 (EOT)

07

Results

Posted Jun 2, 2026

Participant flow

This study was conducted at 44 sites in 14 countries (Australia, Canada, Czechia, Germany, Hong Kong, Hungary, Israel, Japan, Netherlands, New Zealand, Russia, Spain, Taiwan, and United States of America).

Participant flow — Overall Study
MilestoneCSL312 (Garadacimab)
Started161
Completed146
Not completed15
Withdrew: Adverse event4
Withdrew: Pregnancy1
Withdrew: Lack of efficacy1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject3
Withdrew: Physician decision2
Withdrew: Site terminated by sponsor due to war3

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)
Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
ParticipantsParticipants With c1-esterase Inhibitor (c1-INH) Hereditary Angioedema (HAE)
Number of Participants With Treatment-emergent Adverse Events (TEAE)146
PrimaryPercentage of Participants With TEAE

The percentage of participants was rounded to one place of decimal.

Time frame:
Approximately up to 54 months
Reported as:
Number · Percentage of participants
Percentage of Participants With TEAE
Percentage of participantsParticipants With c1-INH HAE
Percentage of Participants With TEAE91.8
PrimaryNumber of TEAE
Time frame:
Approximately up to 54 months
Reported as:
Number · Events
Number of TEAE
EventsParticipants With c1-INH HAE
Number of TEAE1196
PrimaryTEAE Rates Per Injection

The TEAE rate per injection was calculated as the number of TEAE/ total number of injections. The number of injections was defined as the total injections received by participants during the respective safety evaluation period.

Time frame:
Approximately up to 54 months
Reported as:
Number · Number of TEAE per injection
TEAE Rates Per Injection
Number of TEAE per injectionParticipants With c1-INH HAE
TEAE Rates Per Injection0.20
PrimaryTEAE Rates Per Participant Year

The TEAE rate per participant year was calculated as the total number of TEAE/ participant years. Participant years was defined as the sum of the time (in years) that participant were exposed to study treatment during the respective safety evaluation period.

Time frame:
Approximately up to 54 months
Reported as:
Number · Number of TEAE per participant year
TEAE Rates Per Participant Year
Number of TEAE per participant yearParticipants With c1-INH HAE
TEAE Rates Per Participant Year2.26
SecondaryThe Time-normalized Number (Per Month) of Hereditary Angioedema (HAE) Attacks During the Run-in Period and Treatment Period

Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*30.4375.

Time frame:
Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per month
The Time-normalized Number (Per Month) of Hereditary Angioedema (HAE) Attacks During the Run-in Period and Treatment Period
Number of HAE attacks per monthCSL312 (Garadacimab)
Per month (Run-in Period)2.85 (2.61 to 3.17)
Per month (Treatment Period)0.02 (0.00 to 0.02)
SecondaryThe Time-normalized Number (Per Year) of HAE Attacks During Treatment Period

Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*365.25.

Time frame:
Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per year
The Time-normalized Number (Per Year) of HAE Attacks During Treatment Period
Number of HAE attacks per yearCSL312 (Garadacimab)
The Time-normalized Number (Per Year) of HAE Attacks During Treatment Period0.25 (0.00 to 0.28)
SecondaryPercentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period

The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as: 100\*(1- time normalized number of HAE attacks per month during Treatment Period/time-normalized number of HAE attacks per month during Run-in Period).

Time frame:
Run-in Period: Up to 60 days and Treatment Period: Approximately up to 52 months
Reported as:
Mean · Percentage reduction in HAE attacks
Percentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period
Percentage reduction in HAE attacksCSL312 (Garadacimab)
Percentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period95.41 ± 11.073
SecondaryNumber of Participants With Percentage Reduction (of >=50%, >=70%, >=90%, and 100%) in HAE Attacks

The number of participants who achieved a percentage reduction in HAE attacks of \>=50% (also considered as responders), \>=70%, \>=90%, and 100% (attack free) during the Treatment Period compared with the Run-in Period. The percentage reduction in the time-normalized number of HAE attacks per month was calculated as 100\*\[1 - (time-normalized number of HAE attacks per month under CSL312 treatment / time-normalized number of HAE attacks per month during Run-in Period)\].

Time frame:
Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months
Reported as:
Count of participants · Participants
Number of Participants With Percentage Reduction (of >=50%, >=70%, >=90%, and 100%) in HAE Attacks
ParticipantsCSL312 (Garadacimab)
>= 50%158
>= 70%155
>= 90%139
Attack free (Reduction of 100%)76
SecondaryThe Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment

Time-normalized number of HAE attacks per month requiring on demand treatment was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*30.4375.

Time frame:
Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per month
The Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment
Number of HAE attacks per monthCSL312 (Garadacimab)
The Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment0.00 (0.00 to 0.02)
SecondaryThe Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment

Time-normalized number of HAE attacks requiring on demand treatment per year was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*365.25.

Time frame:
Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per year
The Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment
Number of HAE attacks per yearCSL312 (Garadacimab)
The Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment0.00 (0.00 to 0.25)
SecondaryThe Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks

Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\]\*30.4375.

Time frame:
Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per month
The Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks
Number of HAE attacks per monthCSL312 (Garadacimab)
The Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks0.00 (0.00 to 0.02)
SecondaryThe Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks

Time-normalized number of moderate or severe HAE attacks per year during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks /length of participant treatment in days\]\*365.25.

Time frame:
Approximately up to 52 months
Reported as:
Median · Number of HAE attacks per year
The Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks
Number of HAE attacks per yearCSL312 (Garadacimab)
The Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks0.00 (0.00 to 0.23)
SecondaryNumber of Participants Rating Their Response to Therapy as Good or Excellent

Number of participants rating their response to therapy as good or excellent was evaluated as per Subject's Global Assessment of Response to Therapy (SGART) questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure.

Time frame:
At Months 12, 24, and 36
Reported as:
Count of participants · Participants
Number of Participants Rating Their Response to Therapy as Good or Excellent
ParticipantsCSL312 (Garadacimab)
At Month 12136
At Month 24130
At Month 36108
SecondaryPercentage of Participants Rating Their Response to Therapy as Good or Excellent

Percentage of participants rating their response to therapy as good or excellent was evaluated as per SGART questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure. The percentage of participants was rounded to one place of decimal.

Time frame:
At Months 12, 24, and 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Rating Their Response to Therapy as Good or Excellent
Percentage of ParticipantsCSL312 (Garadacimab)
At Month 1293.8
At Month 2497.7
At Month 3694.7
SecondaryNumber of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
ParticipantsCSL312 (Garadacimab)
SAE14
Experiencing Death0
Related TEAE24
TEAE leading to study discontinuation4
SecondaryPercentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation

The percentage of participants was rounded to one decimal place.

Time frame:
Approximately up to 54 months
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Percentage of participantsCSL312 (Garadacimab)
SAE8.7
Experiencing Death0
Related TEAE14.9
TEAE leading to study discontinuation2.5
SecondaryNumber of Participants Experiencing TEAE by Severity

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing TEAE by Severity
ParticipantsCSL312 (Garadacimab)
Mild121
Moderate111
Severe20
Missing1
SecondaryPercentage of Participants Experiencing TEAE by Severity

Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one decimal place.

Time frame:
Approximately up to 54 months
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing TEAE by Severity
Percentage of participantsCSL312 (Garadacimab)
Mild75.2
Moderate68.9
Severe12.4
Missing0.6
SecondaryNumber of Participants Experiencing Adverse Events of Special Interest (AESI)

The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.

Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events of Special Interest (AESI)
ParticipantsCSL312 (Garadacimab)
Thromboembolic events (Investigator)0
Abnormal bleeding events (Investigator)0
Hypersensitivity including anaphylaxis (Investigator)0
SecondaryPercentage of Participants Experiencing AESI

The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.

Time frame:
Approximately up to 54 months
Reported as:
Number · Percenatge of participants
Percentage of Participants Experiencing AESI
Percenatge of participantsCSL312 (Garadacimab)
Thromboembolic events (Investigator)0
Abnormal bleeding events (Investigator)0
Hypersensitivity including anaphylaxis (Investigator)0
SecondaryNumber of Participants With Laboratory Findings Reported as TEAE
Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Findings Reported as TEAE
ParticipantsCSL312 (Garadacimab)
Bacterial test positive6
Urinary squamous epithelial cells increased4
White blood cells urine positive2
Crystal urine present2
Red blood cells urine positive2
White blood cell count increased2
Neutrophil count increased1
Bilirubin conjugated increased1
Blood bilirubin increased1
Blood calcium decreased1
Blood creatinine increased1
Crystalluria1
Cystitis1
Fibrin D dimer increased1
Gastroenteritis1
Hyperbilirubinaemia1
Lymphocyte count decreased1
Neutrophil count decreased1
Nitrite urine present1
Platelet count increased1
Protein urine present1
Specific gravity urine increased1
Thrombocytopenia1
Urinary occult blood positive1
Urinary sediment present1
Urinary tract infection1
Urine analysis abnormal1
Urine ketone body present1
SecondaryPercentage of Participants With Laboratory Findings Reported as TEAE

The percentage of participant was rounded to one place of decimal.

Time frame:
Approximately up to 54 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Laboratory Findings Reported as TEAE
Percentage of ParticipantsCSL312 (Garadacimab)
Bacterial test positive3.7
Urinary squamous epithelial cells increased2.5
White blood cells urine positive1.2
Crystal urine present1.2
Red blood cells urine positive1.2
White blood cell count increased1.2
Neutrophil count increased0.6
Bilirubin conjugated increased0.6
Blood bilirubin increased0.6
Blood calcium decreased0.6
Blood creatinine increased0.6
Crystalluria0.6
Cystitis0.6
Fibrin D dimer increased0.6
Gastroenteritis0.6
Hyperbilirubinaemia0.6
Lymphocyte count decreased0.6
Neutrophil count decreased0.6
Nitrite urine present0.6
Platelet count increased0.6
Protein urine present0.6
Specific gravity urine increased0.6
Thrombocytopenia0.6
Urinary occult blood positive0.6
Urinary sediment present0.6
Urinary tract infection0.6
Urine analysis abnormal0.6
Urine ketone body present0.6
SecondaryNumber of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE
Time frame:
Approximately up to 54 months
Reported as:
Count of participants · Participants
Number of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE
ParticipantsParticipants With nC1-INH HAE
Number of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE2
SecondaryPercentage of Participants With nC1-INH Experiencing TEAE
Time frame:
Approximately up to 54 months
Reported as:
Number · Percenatge of participants
Percentage of Participants With nC1-INH Experiencing TEAE
Percenatge of participantsParticipants With nC1-INH HAE
Percentage of Participants With nC1-INH Experiencing TEAE100
SecondaryNumber of Participants With Anti-CSL312 Antibodies
Time frame:
At Day 1, Months 6, 12, 36 and 43 (end of treatment [EOT])
Reported as:
Count of participants · Participants
Number of Participants With Anti-CSL312 Antibodies
ParticipantsCSL312 (Garadacimab)
Day 1: Positive1
Month 6: Positive1
Month 12: Positive4
Month 24: Positive0
Month 36: Positive0
EOT: Positive2
SecondaryPercentage of Participants With Anti-CSL312 Antibodies

The percentage of participants was rounded to one decimal place.

Time frame:
At Day 1, Months 6, 12, 36 and 43 (EOT)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-CSL312 Antibodies
Percentage of participantsCSL312 (Garadacimab)
Day 1: Positive0.6
Month 6: Positive0.6
Month 12: Positive2.5
Month 24: Positive0
Month 36: Positive0
EOT: Positive1.2

Adverse events

Collected over Approximately up to 54 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CSL312 (Garadacimab)0/161 (0%)14/161 (8.7%)147/161 (91.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCSL312 (Garadacimab)
COVID-19Infections and infestations2/161
Appendicitis perforatedInfections and infestations1/161
GastroenteritisInfections and infestations1/161
Gastroenteritis viralInfections and infestations1/161
SinusitisInfections and infestations1/161
Craniofacial injuryInjury, poisoning and procedural complications1/161
Hand fractureInjury, poisoning and procedural complications1/161
Hereditary angioedemaCongenital, familial and genetic disorders1/161
Abdominal incarcerated herniaGastrointestinal disorders1/161
Food allergyImmune system disorders1/161
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCSL312 (Garadacimab)
COVID-19Infections and infestations67/161
NasopharyngitisInfections and infestations45/161
InfluenzaInfections and infestations17/161
HeadacheNervous system disorders15/161
Upper respiratory tract infectionInfections and infestations14/161
Injection site erythemaGeneral disorders13/161
ArthralgiaMusculoskeletal and connective tissue disorders13/161
Abdominal painGastrointestinal disorders11/161
ToothacheGastrointestinal disorders11/161
SinusitisInfections and infestations10/161

Baseline characteristics

All Treated Participants (ATP) analysis set consisted of all participants in the Screened analysis set who were assigned to treatment.

Age, Continuous
Age, Continuous(Years)CSL312 (Garadacimab)
Mean42.3 ± 15.31
Age, Customized
Age, Customized(Participants)CSL312 (Garadacimab)
<=18 years12
Between 18 and 64 years134
>=65 years15
Sex: Female, Male
Sex: Female, Male(Participants)CSL312 (Garadacimab)
Female101
Male60
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CSL312 (Garadacimab)
Hispanic or Latino9
Not Hispanic or Latino150
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CSL312 (Garadacimab)
American Indian or Alaska Native0
Asian22
Native Hawaiian or Other Pacific Islander0
Black or African American2
White135
More than one race1
Unknown or Not Reported1
08

Study locations

44 sites
  • Clinical Research Center of Alabama
    Birmingham, Alabama 35209, United States
  • Research Solutions of Arizona
    Litchfield Park, Arizona 85340, United States
  • Medical Research of Arizona
    Scottsdale, Arizona 85251, United States
  • Little Rock Allergy & Asthma Clinic
    Little Rock, Arkansas 72205, United States
  • Donald S. Levy M.D.
    Orange, California 92868, United States
  • Raffi Tachdjian MD, Inc.
    Santa Monica, California 90404, United States
  • Allergy & Asthma Clinical Research
    Walnut Creek, California 94598, United States
  • Institute for Asthma and Allergy PC
    Chevy Chase, Maryland 20815, United States
  • Bernstein Clinical Research Center, LLC
    Cincinnati, Ohio 45236, United States
  • PennState Health Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Campbelltown Hospital / Western Sydney University
    Campbelltown, New South Wales 2560, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital, Department of Clinical Immunology
    Murdoch, Western Australia 6150, Australia
  • University of Alberta - Research Transition Facility
    Edmonton, Alberta T6G 2B7, Canada
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
  • Ottawa Allergy Research Corp
    Ottawa, Ontario K1H 1E4, Canada
  • Gordon Sussman Clinical Research
    Toronto, Ontario M3B 3S6, Canada
  • Montreal Clinical Research Institute
    Montreal, Quebec H2W 1R7, Canada
  • University hospital St. Anna Ustav klinicke imunologie a alergologie, Fakultní nemocnice u sv. Anny v Brně
    Brno, 65691, Czechia
  • University Hospital Motol
    Prague, 150 06, Czechia
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Frankfurt
    Frankfurt, 60590, Germany
  • Johannes Gutenberg-Universität KöR, Hautklinik und Poliklinik der Universitätsmedizin, Clinical Research Center
    Mainz, 55131, Germany
  • HZRM Haemophilie Zentrum Rhein Main GmbH
    Mörfelden-Walldorf, 64546, Germany
  • The University of Hong Kong, Queen Mary Hospital
    Hong Kong, Hong Kong
  • Semmelweis Egyetem Altalanos Orvostudományi Kar Belgyógyászati és Hematológiai Klinika
    Budapest, 1088, Hungary
  • Barzilai University Medical Center
    Ashkelon, 7830604, Israel
  • Koga Community Hospital
    Shizuoka, Daikakuji Yaizu-shi 425-0088, Japan
  • Mie University Hospital
    Mie, Edobashi, Tsu-shi Edobashi, Tsu-shi, Japan
  • Juntendo University Hospital
    Tokyo, Hongo Bunkyo-ku 113-8431, Japan
  • Saitama Medical Center
    Saitama, Kamoda Kawagoe-shi 350-8550, Japan
  • St. Marianna University School of Medicine Hospital
    Kanagawa, Kawasaki-shi 216-8511, Japan
  • Clover Hospital
    Kanagawa, Kugenumaishigami, Fujisawa-shi 251-0025, Japan
  • Saiyu Soka Hospital
    Saitama, Matsubara Soka-shi 340-0041, Japan
  • National Hospital Organization Disaster Medical Center
    Tokyo, Midoricho, Tachikawa-shi 190-0014, Japan
  • Saga University Hospital
    Saga, Nebeshima, Saga-shi 849-8501, Japan
  • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital
    Miyakojima-ku, Osaka-shi 534-0021, Japan
  • Amsterdam UMC, location AMC
    Amsterdam, 1105, Netherlands
  • Auckland City Hospital
    Grafton, Auckland 1023, New Zealand
  • NRC Institute of Immunology FMBA Russia
    Moscow, 115522, Russia
  • Hospital Universitari General de La Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Gregorio Marañón, Servicio de Alergia
    Madrid, 28007, Spain
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
09

References and documents

Publications

  • Craig TJ, Guilarte M, Li HH, Anderson J, Martinez Saguer I, Jacobs JS, Tachdjian R, Farkas H, Yang WH, Ohsawa I, Hakl R, Pollen M, Pragst I, Lawo JP, Shetty H, Nenci C, Magerl M. Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis. Adv Ther. 2026 Jun 10. doi: 10.1007/s12325-026-03628-x. Online ahead of print. PubMed 42268494 ↗
  • Guilarte M, Lumry WR, Magerl M, Martinez Saguer I, Reshef A, Sobotkova M, Braverman J, Lawo JP, Wieman L, Nenci C, Katelaris CH. Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema. Allergy Asthma Proc. 2025 May 1;46(3):192-199. doi: 10.2500/aap.2025.46.250027. PubMed 40380363 ↗
  • Staubach P, Craig TJ, Fukuda T, Aygoren-Pursun E, Hakl R, Braverman J, Lawo JP, Pollen M, Nenci C, Li PH, Farkas H. Becoming attack-free further improves health-related quality of life in patients with hereditary angioedema receiving garadacimab. Allergy Asthma Proc. 2025 May 1;46(3):200-208. doi: 10.2500/aap.2025.46.250026. PubMed 40380356 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2025, 55 months.

Results were first posted in Jun 2026, 6 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 55 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Feb 4, 2021
StartActual
Mar 29, 2021
Primary completionActual
Nov 21, 2025
CompletionActual
Nov 21, 2025
Results first posted
Jun 2, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04739059
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Mar 29, 2021
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025
Results posted
Jun 2, 2026
Last update
Jun 2, 2026

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Garadacimab

Start the discussion